Curium Initiates ECLIPSE, a Phase 3 Clinical Trial For Its Investigational Lu 177 PSMA I&T

By GlobeNewswire

St. Louis, MO, Oct. 27, 2021 (GLOBE NEWSWIRE) — Curium announced today that the Company has received a Study May Proceed letter from the U.S. Food and Drug Administration (FDA) to begin its Phase 3 trial with its investigational product lutetium Lu 177 PSMA I&T, a therapeutic radiopharmaceutical that binds to the Prostate-Specific Membrane Antigen (PSMA) protein. Curium is working closely with sites across the U.S. to initiate the ECLIPSE trial (A Multi-Center, Open-Label, Randomized Phase 3 Tr

…read more

Via:: Sports Headlines


Get 20% off hat purchases for ONLY $5! Join our LIDS Club @
%d bloggers like this: